Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Corbus soars on Phase II scleroderma result

Monday, November 14, 2016 9:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) jumped more than two-thirds as a phase II study of its treatment for systemic sclerosis showed significant benefits over a placebo.

In a trial of 42 patients, those taking Resunab registered a 33% improvement registered for lung function, skin hardening and other symptoms compared with zero improvement for the placebo group.

“No drug has ever shown has shown efficacy in scleroderma,” Yuval Cohen, chief executive, told Reuters.

“What we’ve seen here is unprecedented – to get these types of responses in a study that is so short and so small.”

Sclerodama affects about 90,000 people in the US and Europe with no cure or even real understanding of what causes the disease.

Treatments so far have focused on alleviating damage to affected organs, but Resunab tackles the chronic inflammation and fibrosis it causes.

Corbus shares today jumped by 64% to US$9.64 and have risen by nearly 500% so far year.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.